When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant...

    www.idsociety.org/practice-guideline/amr-guidance

    Meropenem, imipenem-cilastatin, or ertapenem are preferred agents; ertapenem offers a more convenient option for patients needing to continue carbapenem therapy in the outpatient setting when oral treatment options are not available.

  3. IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant...

    integ.idsociety.org/practice-guideline/amr-guidance

    Suggested approach: Meropenem, imipenem-cilastatin, or ertapenem are preferred for the treatment of infections outside of the urinary tract caused by ESBL-E. For patients who are critically ill and/or experiencing hypoalbuminemia, meropenem or imipenem-cilastatin are the preferred carbapenems.

  4. Antimicrobial Susceptibility Testing - IDSA

    www.idsociety.org/public-health/antimicrobial-resistance/archive-antimicrobial...

    In June 2010, the Clinical and Laboratory Standards Institute (CLSI) published new MIC and disk diffusion interpretive criteria (i.e., breakpoints) for the Enterobacteriaceae for five cephalosporins, including: and for three carbapenems (imipenem, meropenem, and ertapenem).

  5. Skin and Soft Tissue Infections - IDSA

    www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections

    Hospitalization and empiric antibacterial therapy with vancomycin plus antipseudomonal antibiotics such as cefepime, a carbapenem (imipenem-cilastatin or meropenem or doripenem) or piperacillin-tazobactam is recommended (strong, high).

  6. Table 1. Revised and new CLSI breakpoints† Drug MIC Disk - IDSA

    www.idsociety.org/globalassets/idsa/topics-of-interest/antimicrobial...

    Ertapenem (1g q24) ... ≤1 2 ≥4 ≤4 8 ≥16 ≥23 20-22 ≤19 ≥16 14-15 ≤13 Meropenem (1g q8) ≤1 2 ≥4 ≤4 8 ≥16 ≥23 20-22 ≤19 ≥16 14-15 ≤13 † S, susceptible; l, intermediate; R, resistant ‡ Dosage used to establish breakpoints *NA, not applicable Reference ...

  7. Healthcare-Associated Ventriculitis and Meningitis - IDSA

    www.idsociety.org/practice-guideline/healthcare-associated-ventriculitis-and...

    Vancomycin plus an anti-pseudomonal beta-lactam (such as cefepime, ceftazidime, or meropenem) is recommended as empiric therapy for healthcare-associated ventriculitis and meningitis; the choice of empiric beta-lactam agent should be based on local in vitro susceptibility patterns (strong, low).

  8. IDSA 2015 Clinical Practice Guidelines for the Diagnosis and...

    www.idsociety.org/practice-guideline/vertebral-osteomyelitis

    Native Vertebral Osteomyelitis; NVO; antimicrobial therapy These guidelines are intended for use by infectious disease specialists, orthopedic surgeons, neurosurgeons, radiologists, and other healthcare professionals who care for patients with native vertebral osteomyelitis (NVO).

  9. IDSA Home

    www.idsociety.org/globalassets/bb-complex-pages/idsa/opat-ehandbook/opat_epub...

    IDSA Home

  10. Outpatient and Home Infusion Therapy: List of Codes - IDSA

    www.idsociety.org/globalassets/idsa/professional-development/outpatient-and...

    Outpatient and Home Infusion Therapy: List of Codes. With some insurance carriers, you will need to add modifier -59 to the pushes and/or infusion supplies code. * Home Infusion Therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and ...

  11. EIN - Emerging Infections Network

    ein.idsociety.org/surveys/survey/171

    A urine culture grew Klebsiella pneumoniae resistant to meropenem, ertapenem, nitrofurantoin, TMP/SMX, and ciprofloxacin. a. Indicate which antibiotic you would most realistically choose to treat this patient with cystitis, assuming susceptibility to all of the following (colistin MIC≤2 mcg/ml (I)):